Comparing the Antithrombotic Efficacy of a Humanized Anti-factor IX(a) Monoclonal Antibody (SB 249417) to the Low Molecular Weight Heparin Enoxaparin In a Rat Model of Arterial Thrombosis

详细信息    查看全文

• 作者：Toomey ; John R. ; Blackburn ; Michael N. ; Storer ; Barbara L. ; Valocik ; Richard E. ; Koster ; Paul F. ; et. al.
• 关键词：Antithrombotic ; Factor IX ; Low molecular weight heparin ; Arterial thrombosis ; Monoclonal antibody ; Rat ; Factor IX(a) ; factor IX and factor IXa ; LMWH ; low molecular weight heparin ; UFH ; unfractionated heparin ; aPTT ; activated partial thromboplastin time ; P
• 刊名：Thrombosis Research
• 出版年：2000
• 出版时间：October 1, 2000
• 年：2000
• 卷：100
• 期：1
• 页码：73-79
• 全文大小：94.0 K

文摘

A humanized inhibitory anti-factor IX(a) antibody (SB 249417) has been compared to enoxaparin (Lovenox) in a rat model of arterial thrombosis. Pretreatment of rats with either SB 249417 (3.0 mg/kg, i.v.) or enoxaparin (30.0 mg/kg, i.v. or s.c.) resulted in comparable and significant reductions in thrombus formation. However, the efficacious dose of enoxaparin resulted in >30-fold increase in the aPTT over baseline, while the efficacious dose of SB 249417 prolonged the aPTT by only approximately 3-fold. Additionally, pretreatment with SB 249417 resulted in sustained blood flow and arterial patency throughout the experiment in >80 % of rats treated. In contrast, <30 % of rats pretreated with enoxaparin remained patent throughout the experiment. The data in this report indicate that the selective inhibition of factor IX(a) with the monoclonal antibody SB 249417 produces a superior antithrombotic profile to that of the low molecular weight heparin enoxaparin.